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Abstract
Introduction
Population-based data are limited on how often colorectal cancer
(CRC) is identified through screening or surveillance in asympto-
matic patients versus diagnostic workup for symptoms. We de-
veloped  a  process  for  assessing  CRC  identification  methods
among Medicare-linked CRC cases from a population-based can-
cer registry to assess identification methods (screening/surveil-
lance or diagnostic) among Kansas Medicare beneficiaries.
Methods
New CRC cases diagnosed from 2008 through 2010 were identi-
fied from the Kansas Cancer Registry and matched to Medicare
enrollment and claims files. CRC cases were classified as dia-
gnostic-identified versus screening/surveillance-identified using a
claims-based  algorithm  for  determining  CRC  test  indication.
Factors associated with screening/surveillance-identified CRC
were analyzed using logistic regression.
Results
Nineteen percent of CRC cases among Kansas Medicare benefi-
ciaries were screening/surveillance-identified while 81% were dia-
gnostic-identified. Younger age at diagnosis (65 to 74 years) was
the only factor associated with having screening/surveillance-iden-
tified CRC in multivariable analysis. No association between rur-
al/urban residence and identification method was noted.
Conclusion
Combining administrative claims data with population-based re-
gistry records can offer novel insights into patterns of CRC test
use  and  identification  methods  among people  diagnosed  with
CRC. These techniques could also be extended to other screen-de-
tectable cancers.
Introduction
Colorectal cancer (CRC) is the third most common cancer and
third leading cause of cancer death in Kansas (1). In 2002, the US
Preventive Services Task Force (USPSTF) strongly recommended
that people aged 50 years or older be screened for CRC on the
basis of evidence that screening is effective in reducing CRC mor-
tality rates (2,3). As a result of this recommendation, CRC screen-
ing has been widely promoted by many groups, including the Na-
tional Cancer Institute, the Centers for Disease Control and Pre-
vention (CDC), and the American Cancer Society (ACS). Use of
CRC tests among US adults has been increasing (4–6). From 2000
to 2010, the percentage of US adults aged 50 to 75 receiving any
CRC screening test within recommended intervals increased from
38.6% to 59.1% (4,7). At the same time, CRC incidence has been
declining and the proportion of cases diagnosed at  a localized
stage has been increasing, trends attributed to a combination of
risk-factor reduction and increased screening rates (8). However,
CRC screening rates still lag behind those for other effective can-
cer screening tests. In 2010, less than half of CRC cases were dia-
gnosed at a localized stage in both Kansas (41%) and the United
States (39%) (1,7,9). Although CRC screening is promoted as a
key tool for improving CRC outcomes, few data are available on
how often CRC cases are identified through screening or surveil-
lance  in  asymptomatic  patients  versus  diagnostic  workup  for
symptoms,  particularly  at  the  population  level.  Documenting
trends in CRC identification methods could provide additional in-
sight into the contributions of screening to CRC prevention and
morbidity reduction. In addition, analyses of patient and tumor
characteristics by identification method could identify population
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subgroups not benefiting from CRC screening and tumor sub-
groups not amenable to identification by screening. We sought to
explore the circumstances leading to the identification of CRC, to
examine relationships between identification method and patient
and tumor characteristics, and to develop a process for assessing
CRC identification methods among Medicare-linked CRC cases
from a population-based cancer registry.
Methods
Study population and data sources
This study was approved by the University of Kansas Medical
Center Institutional Review Board. Kansas residents aged 65 years
or  older  who  were  diagnosed  with  invasive  CRC  from  2008
through 2010 were identified from the population-based Kansas
Cancer Registry (n = 2,497) and matched to Medicare enrollment
files using Social  Security numbers,  with further confirmation
based on date of birth, sex, race, and residence zip code. A de-
terministic matching approach was used for the linkage. A total of
2,378 patients (95.2%) were successfully matched between the 2
databases. CRC cases were defined according to the Surveillance,
Epidemiology, and End Results (SEER) Site Recode values for the
Colon (21041–21049, 21051) and Rectum (21052). Only patients
continuously enrolled in both Medicare Parts A and B (fee-for-ser-
vice) with no health maintenance organization coverage during the
year before diagnosis were included. CRC-related diagnoses and
procedures were identified using Part  A inpatient hospital  and
skilled nursing facility claims (MedPAR file), Part A institutional
outpatient provider claims (Outpatient file) and Part B noninstitu-
tional physician/supplier claims (Carrier file). For patients with
multiple CRC primaries diagnosed from 2008 through 2010, the
first  incident case was selected for analysis.  Patients were ex-
cluded if they had a prior invasive CRC (n = 120), were missing
month or day of diagnosis or both (n = 24), were ascertained by
the registry solely on the basis of a death certificate (n = 34), were
eligible for Medicare because of disability or end-stage renal dis-
ease  (n = 166), were not continuously enrolled in Medicare Part A
and Part B in the year before diagnosis (n = 375), or had minimal
or no claims history around their diagnosis date (n = 70). The fi-
nal study population was 1,589 patients.
Assigning CRC identification method
CRC identification method (screening/surveillance vs diagnostic)
was determined by evaluating the indication for use of any CRC-
related tests (colonoscopy, computed tomography [CT] colono-
graphy,  double-contrast  barium enema, fecal  occult  blood test
[FOBT]/fecal immunochemical test [FIT], sigmoidoscopy) docu-
mented in Medicare claims during the 60 days before diagnosis.
Because CRC screening and surveillance are test-based, patients
without a CRC-related test in the 60-day window were assumed to
be diagnostic-identified (n = 256). Current Procedural Termino-
logy  (CPT),  Healthcare  Common  Procedure  Coding  System
(HCPCS), and International Classification of Diseases, Ninth Re-
vision, Clinical Modification (ICD-9-CM) procedure codes were
used to identify CRC-related tests on claims from physician en-
counters, hospital outpatient encounters, and inpatient admissions
(Table 1). For patients who had a colonoscopy claim in the 60-day
window (n = 1,257), the nonparametric classification and regres-
sion tree (CART) algorithm for 2-level colonoscopy indication
(diagnostic vs average-risk screening/high-risk screening/surveil-
lance) developed by Ko et al was applied to determine colono-
scopy indication and corresponding CRC identification method
(10). The CART algorithm uses ICD-9-CM diagnosis codes from
the colonoscopy claim and claims during the year before to de-
termine indication and does not rely on specific colonoscopy pro-
cedure codes. The sensitivity and specificity for this algorithm
were reported as 77% and 90%, respectively, by the authors (10).
For patients who did not have a colonoscopy in the 60-day win-
dow but did have another CRC-related test  (CT colonography,
double-contrast barium enema, FOBT/FIT, sigmoidoscopy) (n =
294), claims from the year before the test date were examined for
CRC symptom ICD-9-CM diagnosis codes (Table 1). Among this
group, patients with 1 or more claims with a CRC symptom dia-
gnosis code were classified as diagnostic-identified. The Figure
summarizes the CRC identification classification results for all pa-
tients.
Figure. Identification method classification process and results for invasive
colorectal cancer (CRC), Kansas Medicare beneficiaries, 2008–2010. “Ko
algorithm”  refers  to  classification  and  regression  tree  algorithm  for
colonoscopy  indication  (diagnostic  vs  average-risk  screening/high-risk
screening/surveillance) developed by Ko et al (10).
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Statistical analyses
Independent variables included age, sex, race, marital status, rural/
urban residence and anatomic site from Kansas Cancer Registry
(KCR) records along with comorbidity score and income level
from Medicare records. A comorbidity score was calculated using
the Charlson comorbidity index as adapted for physician and hos-
pital administrative claims data by the National Cancer Institute
and presented on the SEER-Medicare website (11,12). MedPAR,
Outpatient and Carrier claims from the year preceding diagnosis
were used to determine the comorbidity score. Claims from the 30
days before diagnosis were excluded to avoid identifying complic-
ations or comorbidities resulting from the cancer diagnosis. Pa-
tients were categorized as low-income or not low-income based on
their  eligibility  for  Medicare  premium subsidy (full  or  partial
Medicaid dual-eligibility or Part D Low-Income Subsidy or both)
in any month during the year before diagnosis. Rural/urban resid-
ence was defined using Rural Urban Commuting Area (RUCA)
zip code approximation codes for the patient’s zip code at dia-
gnosis (13). Stage at diagnosis was classified by the SEER Sum-
mary Stage 2000 system as localized, regional, distant, and un-
staged. Associations between categorical variables and CRC iden-
tification method were examined using Pearson χ2 tests. Bivariate
and multiple logistic regressions were used to calculate unadjus-
ted and adjusted odds ratios (ORs) and 95% confidence intervals
(CIs)  for  factors  associated  with  CRC  identification  through
screening/surveillance. All significance tests were 2-sided at the
.05 level. Only independent variables with a P value of <.15 in the
bivariate logistic regression analysis were included in the multiple
logistic regression analysis. SAS version 9.3 for Windows was
used for all analyses.
Results
A total of 1,589 CRC cases who met the study eligibility criteria
were included in the analysis. Of these, 1,333 patients had a claim
for any CRC test in the 60 days before diagnosis. The distribution
of  CRC  test  use  included  1,257  with  colonoscopy,  176  with
FOBT/FIT, 140 with sigmoidoscopy, 40 with double-contrast bari-
um enema and 2 with CT colonography. There were 267 patients
who had claims for more than 1 type of CRC test in the 60 days
before diagnosis. Nineteen percent (n = 294) of the patients were
classified as having screening- or surveillance-identified CRC (Ta-
ble 2). Patients with screening/surveillance-identified CRC were
more likely to be diagnosed at a local stage (P < .001), aged 65 to
74  years  (P  <  .001),  and  married  (P  =  .003).  Patients  with  a
colonoscopy claim were more likely to be classified as having
screening-  or  surveillance-identified  CRC  than  patients  with
claims for another CRC test (23% vs 3%, P < .001).
In the bivariate analysis, younger age, male sex, and being mar-
ried were significantly associated with increased odds of having
screening/surveillance-identified CRC (Table 3). Low-income pa-
tients were significantly less likely to have screening/surveillance-
identified CRC (P = .05). In the multiple logistic regression ana-
lysis, only being aged 65 to 74 years remained a significant pre-
dictor of having screening- or surveillance-identified CRC. Com-
pared with this age group, patients aged 75 to 84 years had 41%
lower odds of having screening- or surveillance-identified CRC;
patients aged 85 years or older (P < .001) had 72% lower odds.
Discussion
In this study we developed a process for assessing CRC identifica-
tion methods among Medicare-linked CRC cases from a popula-
tion-based cancer registry by expanding on a previously published
algorithm for determining colonoscopy indication. To maximize
the number of CRC cases eligible for identification method classi-
fication, we also considered use of other CRC tests and symptom
history among those without colonoscopy claims. Using our meth-
od,  19%  of  the  Medicare-linked  CRC  cases  diagnosed  in
2008–2010 in Kansas were identified through screening or surveil-
lance, while 81% were diagnostic-identified. Our finding of 19%
screening/surveillance-identified in a population-based CRC co-
hort is consistent with that reported in a CRC cohort served by a
single major medical institution (20%) during 2004–2011 (14).
Another study in a health care system and a community hospital
during 2002–2004 found that 9% of CRC cases were screening-
identified (15).
Certain factors could contribute to misclassification of identifica-
tion method for CRC cases. First, it is possible that CRC test pro-
cedure codes and CRC-related symptom diagnosis codes for some
patients were not documented in their Medicare claims history,
either because of coding errors or because claims were sent to an-
other payer (16–19). To minimize the impact of patients with non-
Medicare  primary  payers  before  CRC diagnosis,  we  used  the
primary payer fields in the KCR database to identify patients with
other sources of insurance and manually reviewed the complete-
ness of their claims history. Of the patients included in the study,
only 21 cases (1%) had a sole non-Medicare primary payer in the
KCR database. Second, the 60-day window before diagnosis that
we chose may not have captured all CRC-related tests. Sixteen
percent of the patients (n = 256) in our study did not have a claim
for a CRC test in the 60 days before diagnosis and as a result were
classified as diagnostic-identified. This apparent lack of CRC test-
ing could be legitimate because the patient was diagnosed through
other means (eg, diagnostic imaging) or could be an artifact intro-
duced by inaccurate diagnosis dates.  We further examined the
claims and KCR records for these 256 patients and found that 228
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patients had a claim with a CRC-related symptom code within a
year before diagnosis and an additional 15 patients had symptoms
documented in  the KCR database.  Patients  without  CRC tests
were more likely than their counterpart patients with CRC tests to
have a CPT code documented for a diagnostic radiology proced-
ure of the abdomen or pelvis (X-ray, CT, or MRI) in the 60 days
before diagnosis. These insights increase our level of confidence
in classifying these 256 patients as diagnostic-identified.
We found that CRC patients aged 65 to 74 years and who were
male and married had increased odds of having screening/surveil-
lance-identified CRC compared with their counterparts at the time
of CRC diagnosis. However, younger age at diagnosis was the
only factor associated with having screening/surveillance-identi-
fied CRC after adjusting for sex, marital status, comorbidity index,
and income. Although low income had a marginal association with
increased odds of having diagnostic-identified CRC, the signific-
ance level was diminished after adjusting for other risk factors.
The observed decrease in screening/surveillance-identified CRC
with increasing age could be due to several factors. Changes in
CRC screening recommendations and Medicare coverage for CRC
screening have occurred since 1998 (2,20). The 2002 USPSTF re-
commendation applied to all adults aged 50 or older without re-
gard to an age at which to stop screening, but in 2008 the USP-
STF recommended routine cancer screening to begin at age 50 and
continue only until age 75 (in people with adequate screening his-
tories). It is reasonable to assume that these changes affected vari-
ous age cohorts differently; older patients would receive less life-
time benefit from recent improvements in screening technology
and availability. We did not have access to enough claims history
to evaluate long-term adherence to CRC screening recommenda-
tions for the patients in our study but historically low CRC screen-
ing rates indicate that many of the patients in the older age groups
had an adequate history of negative screenings before their CRC
diagnosis. Independent of screening recommendations, physicians
may be less likely to recommend CRC screening in older people
because of significant comorbidities, limited life expectancy, or
both (21–23).
Understanding CRC screening patterns is important for CRC pre-
vention and control at a population-based level. Unfortunately, es-
timating population-level use of CRC screening and the extent to
which it contributes to CRC identification remains challenging,
because no single data set is readily available to address this ques-
tion.  Various  data  sources  including  Medicare  and  Medicaid
claims files, medical records, and surveys have been used to ad-
dress this question but each has its own limitations and unique is-
sues. Still, no single source exists for reliable information about
how frequently CRC is identified through screening versus dia-
gnostic  workup.  To examine CRC identification methods,  our
study not only used Medicare claims files to identify CRC tests
but also considered CRC-related symptoms documented in the
Medicare claims files as well as data in the Kansas Cancer Re-
gistry.
As with any evaluation of clinical practice that relies on adminis-
trative claims data, a limitation of our study is the generalizability
of our findings. The clinical experiences of the Medicare popula-
tion and the way these experiences are reflected in their claims
history may not be generalizable to other groups. However, des-
pite this limitation, we believe that the combination of administrat-
ive claims data with population-based registry records can offer
novel and important insights into screening patterns and identifica-
tion methods among people diagnosed with CRC and that these
techniques could also be extended to other screen-detectable can-
cers.
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Tables
Table 1. Procedure Codes Used to Identify CRC Tests and Diagnosis Codes Used to Identify CRC Symptoms in Medicare
Claims
Tests and Symptoms CPT Procedure
HCPCS
Procedure ICD-9-CM Procedure ICD-9-CM Diagnosis
CRC tests
Colonoscopy 44388–44394, 44397, 45355,
45378–45387, 45391, 45392
G0105, G0121 45.21–45.23, 45.25,
45.41–45.43, 48.36
—
CT colonography 0066T, 0067T, 74261–74263 — — —
Double-contrast barium
enema
74270, 74280 G0106, G0120,
G0122
— —
FOBT/FIT 82270–82274 G0107, G0328 — —
Sigmoidoscopy 45300, 45303, 45305,
45307–45309, 45315, 45317,
45320, 45321, 45327,
45330–45342, 45345
G0104 45.24, 48.21–48.25 —
CRC symptoms
Abdominal mass — — — 789.30–789.39
Abdominal/rectal pain — — — 569.42, 789.00–789.07,
789.09
Anemia (iron deficiency
and NOS)
— — — 280.0, 280.9, 285.1, 285.9
Change in bowel habits — — — 787.99
Constipation — — — 564.00–564.02, 564.09
Diarrhea — — — 787.91
Enteritis and colitis — — — 555.1, 555.2, 555.9,
556.0–556.5, 556.8–
557.1, 557.9, 558.1–558.4
Gastrointestinal bleeding — — — 569.3, 578.1, 578.9, 792.1
Weight loss — — — 783.21
Abbreviations: —, not applicable, CRC, colorectal cancer; CPT, Current Procedural Terminology; CT, computed tomography; FOBT, fecal occult blood test;
FIT, fecal immunochemical test; HCPCS, Healthcare Common Procedure Coding System; ICD-9-CM, International Classification of Diseases, Ninth Revi-
sion, Clinical Modification; NOS, not otherwise specified.
PREVENTING CHRONIC DISEASE VOLUME 12, E107
PUBLIC HEALTH RESEARCH, PRACTICE, AND POLICY           JULY 2015
The opinions expressed by authors contributing to this journal do not necessarily reflect the opinions of the U.S. Department of Health and Human Services,
the Public Health Service, the Centers for Disease Control and Prevention, or the authors’ affiliated institutions.
6       Centers for Disease Control and Prevention  •  www.cdc.gov/pcd/issues/2015/14_0543.htm
Table 2. Characteristics of Kansas Medicare Beneficiaries Diagnosed With Invasive Colorectal Cancer by Identification
Method, 2008–2010
Demographic
Variables
Identification Method, N (%)
P Valuec
All (n = 1,589,
100%)
Screening/Surveillance-identified (n =
294, 19%)
Diagnostic-identified (n =
1,295, 81%)
Diagnosis year
2008 554 (35) 104 (35) 450 (35)
.572009 531 (33) 91 (31) 440 (34)
2010 504 (32) 99 (34) 405 (31)
Age at diagnosis (years)
65–74 529 (33) 138 (47) 391 (30)
<.00175–84 692 (44) 123 (42) 569 (44)
≥85 368 (23) 33 (11) 335 (26)
Sex
Male 717 (45) 148 (50) 569 (44)
.05
Female 872 (55) 146 (50) 726 (56)
Race
White/Other 1,538 (97) 287 (98) 1,251 (97)
.37
Black 51 (3) 7 (2) 44 (3)
Marital statusa
Married 775 (51) 162 (60) 613 (50)
.003
Not married 733 (49) 110 (40) 623 (50)
Charlson comorbidity index
0 789 (50) 162 (55) 627 (48)
.101–2 631 (40) 107 (36) 524 (40)
≥3 169 (11) 25 (9) 144 (11)
Income
Low-income 175 (11) 23 (8) 152 (12)
.05
Not low-income 1,414 (89) 271 (92) 1,143 (88)
Rural/urban residenceb
Urban 673 (42) 137 (47) 536 (41)
.35
Large rural 385 (24) 66 (22) 319 (25)
Small rural 201 (13) 31 (11) 170 (13)
Isolated 329 (21) 60 (20) 269 (21)
Stage at diagnosis
Local 739 (47) 181 (62) 558 (43)
<.001
Regional 507 (32) 78 (27) 429 (33)
a Missing marital status (n = 81).
b Missing rural/urban residence (n = 1).
c P values calculated using Pearson χ2 test.
(continued on next page)
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(continued)
Table 2. Characteristics of Kansas Medicare Beneficiaries Diagnosed With Invasive Colorectal Cancer by Identification
Method, 2008–2010
Demographic
Variables
Identification Method, N (%)
P Valuec
All (n = 1,589,
100%)
Screening/Surveillance-identified (n =
294, 19%)
Diagnostic-identified (n =
1,295, 81%)
Distant 247 (16) 18 (6) 229 (18)
Unstaged 96 (6) 17 (6) 79 (6)
Anatomic site
Colon 1,363 (86) 257 (87) 1,106 (85)
.37
Rectum 226 (14) 37 (13) 189 (15)
a Missing marital status (n = 81).
b Missing rural/urban residence (n = 1).
c P values calculated using Pearson χ2 test.
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Table 3. Predictors of Screening/Surveillance-Identified Colorectal Cancer Among Kansas Medicare Beneficiaries,
2008–2010
Demographic Factor Unadjusted OR (95% CI)c P Value Adjusted OR (95% CI)c P Value
Age at diagnosis, y
65–74 1 [Reference]
<.001
1 [Reference]
<.00175–84 0.61 (0.47–0.81) 0.59 (0.45–0.79)
>85 0.28 (0.19–0.42) 0.28 (0.18–0.44)
Sex
Female 1 [Reference]
.05
1 [Reference]
.72
Male 1.29 (1.00–1.67) 1.05 (0.79–1.40)
Race
White/Other 1 [Reference]
.38 NA
Black 0.69 (0.31–1.56)
Marital statusa
Not married 1 [Reference]
.003
1 [Reference]
.37
Married 1.50 (1.15–1.95) 1.15 (0.85–1.55)
Charlson comorbidity index
0 1 [Reference]
.10
1 [Reference]
.411–2 0.79 (0.60–1.04) 0.84 (0.63–1.12)
>3 0.67 (0.42–1.06) 0.81 (0.50–1.31)
Income
Low-income 1 [Reference]
.05
1 [Reference]
.12
Not low-income 1.57 (0.99–2.48) 1.49 (0.91–2.44)
Rural/urban residenceb
Urban 1 [Reference]
.35 NA
Large rural 0.81 (0.59–1.12))
Small rural 0.71 (0.47–1.10)
Isolated 0.87 (0.62–1.22)
Anatomic site
Colon 1 [Reference]
.37 NA
Rectum 0.84 (0.58–1.23)
Abbreviations: CI, confidence interval; NA, factors were not included in adjusted odds ratio analysis; OR, odds ratio.
a Missing marital status (n = 81).
b Missing rural/urban residence (n = 1).
c P values calculated using Wald χ2 test.
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